Pramipexole Immediate Release

DRUG5 trials

Sponsors

Boehringer Ingelheim, Stanford University

Conditions

Depression - Major Depressive DisorderHealthyParkinson Disease

Phase 1

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

CompletedNCT01214109

Boehringer IngelheimHealthy

Start: 2010-12-31Updated: 2014-06-27

Phase 2

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

CompletedNCT00560508

Boehringer IngelheimParkinson Disease

Start: 2007-11-30Updated: 2014-07-31

Stratified Pharmacological Approaches for Regulating Circuit-Level Effects

RecruitingNCT07022405

Stanford UniversityDepression - Major Depressive Disorder

Start: 2026-01-23End: 2030-08-01Target: 60Updated: 2026-05-15

Phase 3

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

CompletedNCT00558025

Boehringer IngelheimParkinson Disease

Start: 2007-10-31Updated: 2014-05-16

Unknown Phase

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

CompletedNCT00651183

Boehringer IngelheimParkinson Disease

End: 2008-04-30Updated: 2014-05-20